Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensi
May 13 2009 - 8:30AM
PR Newswire (US)
Company's New Smartlipo MPX 46 Watts Enables Physicians to Melt and
Remove Larger Areas of Fat 50% Faster, with Superior Patient Safety
WESTFORD, Mass., May 13 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ: CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today introduced
the multi-wavelength Smartlipo MPX 46 watts, the latest and most
powerful advance in the company's acclaimed Smartlipo platform of
minimally invasive workstations for LaserBodySculpting. The 46-watt
workstation enables a physician to liquefy and remove larger areas
of unwanted fat in about half the time required by the original
32-watt Smartlipo MPX. Like the original Smartlipo MPX, the 46-watt
workstation is equipped with ThermaGuide, the latest in Cynosure's
proprietary SmartSense family of intelligent energy delivery
systems. ThermaGuide is designed to work in harmony with the laser.
It continually monitors the temperature under the skin, and
controls the output of energy, helping to ensure that the treatment
area remains within a safe and an optimal temperature range for fat
removal and tissue tightening through tissue coagulation. Cynosure
has received U.S. Food and Drug Administration clearance to market
the Smartlipo MPX. The company launched its 46-watt workstation at
the recent American Society for Aesthetic Plastic Surgery's 42nd
Annual Meeting. "In my experience, no other laser-assisted
lipolysis technology approaches the quality, safety or
effectiveness of Cynosure's 46-watt Smartlipo MPX," said John W.
Decorato, M.D., a board certified plastic surgeon in Staten Island,
NY. "The nearly 50 percent increase in power allows me to treat
larger areas, and multiple areas, with a faster response. Smartlipo
MPX also is the only lipolysis technology on the market equipped
with temperature sensing and control, a layer of safety that is
unmatched in the industry." "With the introduction of Smartlipo MPX
46 watts, we believe that we have strengthened the competitive
advantage of our laser lipolysis technology not only from the
standpoint of efficacy, but also in terms of patient safety," said
Cynosure President and Chief Executive Officer Michael Davin.
Laser-assisted lipolysis with Smartlipo MPX is performed under
local anesthesia, allowing a patient to go home the same day as the
procedure is performed. "Compared with liposuction, the return to
normal activities is much faster following a Smartlipo MPX
procedure," Dr. Decorato said. "With Smartlipo MPX, the laser
actually liquefies the fat, allowing it to be easily aspirated, as
opposed to the vigorous mechanical suction of fat involved with
liposuction, which can cause significant swelling and soft tissue
trauma." John Milllard, M.D., a board certified plastic surgeon
based in Denver, said he was able to aspirate approximately 1200 mL
of fat, the equivalent of roughly 5 cups, in 10 minutes with the
46-watt Smartlipo MPX. "I would never be able to obtain this amount
this quickly and with such little effort using suction-assisted
lipoplasty alone," he said. "The 46-watt MultiPlex makes it
possible to perform procedures faster. Smartlipo MPX has enabled me
to add two entirely new patient demographics to my practice:
thinner patients and patients with areas of elastosis that
typically could not be treated with traditional liposuction
methods." Smartlipo MPX uses Cynosure's patented MultiPlex
technology to combine the benefits of the 1064-nm and 1320-nm
wavelengths in one laser output. MultiPlex technology enables the
workstation's two wavelengths to be fired sequentially, creating a
blended thermal and photomechanical effect that efficiently
liquefies fat and tightens skin through collagen remodeling. The
two wavelengths can also be used individually, and each offers
unique characteristics. The 30-watt 1064-nm wavelength disrupts a
broad region of tissue while heating the treated areas evenly. The
1064-nm wavelength also mediates blood vessel coagulation enhancing
hemostasis. The 16-watt 1320-nm wavelength is highly concentrated
with minimal scatter, and is rapidly absorbed by the water in the
tissue, which makes it highly effective in the disruption of fat
and treatment of skin. Research presented at the 2009 American
Society for Laser Medicine and Surgery Annual Conference
demonstrates with statistical significance that Smartlipo MPX
tightens skin and shrinks skin tissue more efficaciously than skin
treated with liposuction alone. "Clinical research played a key
role in the development of this technology," Davin said. "Prior to
increasing the power of the system, we conducted extensive clinical
studies to identify an optimal temperature threshold at which laser
energy would effectively emulsify fat cells and tighten tissue. We
developed an array of intelligent motion and temperature sensing
technologies that automatically govern the flow of energy and
prevent the system from exceeding temperature thresholds. These are
tangible and fundamental innovations that we believe distinguish
our laser lipolysis technology and reflect our commitment to the
highest degree of patient care." About Cynosure, Inc. Cynosure,
Inc. develops and markets aesthetic treatment systems that are used
by physicians and other practitioners to perform non-invasive and
minimally invasive procedures to remove hair, treat vascular and
pigmented lesions, rejuvenate the skin, liquefy and remove unwanted
fat through laser lipolysis and temporarily reduce the appearance
of cellulite. Cynosure's products include a broad range of laser
and other light-based energy sources, including Alexandrite, pulsed
dye, Nd:YAG and diode lasers, as well as intense pulsed light.
Cynosure was founded in 1991. For corporate or product information,
contact Cynosure at 800-886-2966, or visit
http://www.cynosure.com/. Forward-Looking Statements Any statements
in this press release about future expectations, plans and
prospects for Cynosure, Inc., including statements about
expectations for its new Smartlipo MPX 46 watts as well as other
statements containing the words "believes," "anticipates," "plans,"
"expects," "will" and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the global
economic recession and its effects on the aesthetic laser industry,
Cynosure's history of operating losses, its reliance on sole source
suppliers, the inability to accurately predict the timing or
outcome of regulatory decisions, changes in consumer preferences,
competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which
are filed with the Securities and Exchange Commission. In addition,
the forward-looking statements included in this press release
represent Cynosure's views as of the date of this press release.
Cynosure anticipates that subsequent events and developments will
cause its views to change. However, while Cynosure may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Contact: Scott Solomon Vice President Sharon
Merrill Associates, Inc. 617-542-5300 DATASOURCE: Cynosure, Inc.
CONTACT: Scott Solomon, Vice President, Sharon Merrill Associates,
Inc., +1-617-542-5300, , for Cynosure, Inc. Web Site:
http://www.cynosure.com/
Copyright